相关临床试验
2
0 进行中
药物批准
4
批准总数
监管机构
1
监管机构数
成立时间
N/A
已完成
1
50.0%
招募中
1
50.0%
- Actress Chrissy Metz, a self-described "biggest skeptic," began GLP-1 therapy through telehealth company Ro after listening to a friend's "very thorough" research. - Metz reports the medication helped reduce inflammation, improve lab and blood work, and quiet "food noise," enabling her to perform eight shows weekly in Broadway's & Juliet. - She emphasizes she did not pursue the treatment "purely for vanity's sake," but to prioritize her long-term health and future well-being. - Metz hopes her vulnerability about the GLP-1 journey opens conversation and encourages others to make health choices despite fear of public judgment.
- Serena Williams returned to professional tennis at Queen's Club, winning her doubles match while openly using GLP-1 drug Zepbound for weight management. - WADA has been monitoring semaglutide and tirzepatide since 2024 to detect potential patterns of misuse in sport, though they remain unprohibited. - Experts note GLP-1s' muscle-wasting effects may complicate classification as performance-enhancing, while new formulations with fewer side effects could shift the debate. - Williams stated the medication helped her lose 34 pounds post-pregnancy and improved joint mobility, saying she wished she had used it during her playing career.
- Ro's peer-reviewed study published in Obesity journal shows patients achieved 16.6% average body weight loss over 68 weeks with semaglutide via telehealth. - The study represents the first evaluation of long-term weight loss and safety outcomes for semaglutide treatment through telehealth platforms. - Results demonstrate that 95.4% of patients achieved ≥5% weight loss and 82.0% achieved ≥10% weight loss, with safety profiles consistent with clinical trials. - The research validates telehealth as an effective delivery method for GLP-1 obesity treatments, potentially expanding access to weight management care.
